Clinical Analysis Of 52 Recurrent Ovarian Cancer Patients

Background:Ovarian cancer has the third highest incidence of any gynecologic malignancy. According to the recent statistics of SEER, about 20180 women were diagnosed as ovarian cancer, and 15310 women were died from it. Because ovaries are located in deep pelvic cavity, it usually lacks significant symptoms and signs, what is more, effective screening technique is also lacking, early diagnosis of ovarian cancer poses a great threat,70% of patients were diagnosed when they were at advanced stage. Currently the standard treatment option for ovarian cancer is a multimodality treatment, which includes cytoreduction surgery plus platinum based chemotherapy. By the recent advances in surgical techniques and advent of novel drugs, response rate of first line chemotherapy reached 70-80%, and the survival of ovarian cancer patients was increased. But many patients will have recurrence, because of drug resistance, so it is mandatory to administer nonplatinum based drugs for such patients. It ovarian cancer once relapse, the mainstay treatment option is palliative therapy. The treatment aims to relieve symptoms, improve the quality of life, and prolong the progress free survivals (PFS) and overall survivals. This study focuses on the prognostic factors of recurrent ovarian cancer.2. Materials and MethodsWe retrospectively analyzed recurrent ovarian cancer patients from 2004 to 2007, and follow-up was conducted for 52 patients (7 patients still alive). Follow-up deadline was April 2011. We adopted the diagnostic standard:1) Significant increase in serum CA125 level; 2) Mass on routine examination; 3) Radiologically proven mass in the pelvic cavity; 4) Ascites; 5) Unknown intestinal obstruction; Patients were classified and analyzed by their age, size of the residual tumor, and frequency of chemotherapy. Data were analyzed by SPSS Statistics, Cox proportional hazard regression model was used for survival analysis.3. Results:Progress free survival (PFS) is associated with overall survival (OS). Longer the PFS, longer the OS (P< 0.01). And the overall survival is influenced by the size of the residual tumor, frequency of chemotherapy and the staging (P<0.05).Conclusion:1. PFS of initiative treatment of ovarian epithelial cancer is associated with OS after recurrences. Longer the PFS, longer the OS.2. Initiative staging of ovarian epithelial cancer, the size of the residual tumor, initiative postoperative chemotherapy are associated with PFS. Early stage and sufficient postoperative chemotherapy are closely related to PFS, but the relation of different pathologic subtype and PFS is still needed further investigation.